Motley Fool
3 Biotech Stocks to Buy in April
Biotech stocks, in general, again performed dismally in the first quarter of 2022. Here’s why they chose Amgen (NASDAQ: AMGN), Jazz Pharmaceuticals (NASDAQ: JAZZ), and Novocure (NASDAQ: NVCR). David Jagielski (Amgen): With new COVID-19 cases down significantly from where they were at the start of the year, there’s optimism that hospitals and the economy as a whole can return to normal in the near future.
